← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
dinutuximab beta
L01FX06
Forms & Strengths
- Concentrate for solution for infusion 20mg/mL
Adult Dosing
- 20mg/m²/day IV over 1 hour for 5 days, repeated every 4 weeks for a maximum of 5 cycles
Pediatric Dosing
- 20mg/m²/day IV over 1 hour for 5 days, repeated every 4 weeks for a maximum of 5 cycles, for high-risk neuroblastoma
Indications
- High-risk neuroblastoma in patients from 12 months to 17 years of age
Mechanism of Action
- Binding to GD2 antigen on cell surface, inducing cell lysis and antibody-dependent cellular cytotoxicity
Contraindications
- Hypersensitivity to dinutuximab beta, murine proteins or excipients
Adverse Reactions
- Pain, hypersensitivity reactions, nausea, vomiting, diarrhea, capillary leak syndrome
Drug Interactions
- Concomitant use with granulocyte-colony stimulating factor may increase risk of myelosuppression
Curated Content: Needs Vetting Before Put to Clinical Use